Back to Search
Start Over
Rozanolixizumab responder and minimal symptom expression rates in generalized myasthenia gravis: Pooled phase 3 and extension studies.
- Source :
-
Journal of the Neurological Sciences . 2023 Supplement, Vol. 455, pN.PAG-N.PAG. 1p. - Publication Year :
- 2023
- Subjects :
- *MYASTHENIA gravis
*SYMPTOMS
Subjects
Details
- Language :
- English
- ISSN :
- 0022510X
- Volume :
- 455
- Database :
- Academic Search Index
- Journal :
- Journal of the Neurological Sciences
- Publication Type :
- Academic Journal
- Accession number :
- 174467898
- Full Text :
- https://doi.org/10.1016/j.jns.2023.122016